PCI Biotech Holding ASA (FRA:4QG) 3-Year EBITDA Growth Rate : 42.80% (As of Dec. 2024)

View and export this data going back to 2008. Start your Free Trial

What is PCI Biotech Holding ASA 3-Year EBITDA Growth Rate?

PCI Biotech Holding ASA's EBITDA per Share for the six months ended in Dec. 2024 was €-0.02.

During the past 3 years, the average EBITDA Per Share Growth Rate was 42.80% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 33.60% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 13.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of PCI Biotech Holding ASA was 42.80% per year. The lowest was -36.00% per year. And the median was 0.95% per year.

Competitive Comparison of PCI Biotech Holding ASA's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, PCI Biotech Holding ASA's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PCI Biotech Holding ASA's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where PCI Biotech Holding ASA's 3-Year EBITDA Growth Rate falls into.

Save Embed

;

Save Embed

;

PCI Biotech Holding ASA 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

PCI Biotech Holding ASA (FRA:4QG) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

PCI Biotech Holding ASA 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of PCI Biotech Holding ASA's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

PCI Biotech Holding ASA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (FRA:4QG) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

PCIB:Norway 0JGL:UK

Address

Ullernchausseen 64, Oslo, NOR, N-0379

Website

https://www.pcibiotech.com

PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.

PCI Biotech Holding ASA Headlines

No Headlines